王金华，2004年毕业于北京大学。 2004-2006年在中国协和协和大学，中国医学科学院药物研究所从事博士后研究。 2006年-2007在美国Case Western Reserve University， Department of Neuropathology任Research Associate。2007-2015年在美国John Wayne Cancer Institute先后任Medical scientist，Assistant professor, faculty。2015年3月回中国医学科学院药物研究所工作。现任中国医学科学院药物研究所国家新药筛选中心副主任，实聘课题组长；中国医学科学院药物研究所、北京协和医学院引进人才、研究员、“协和学者” 特聘教授、博士生导师、中国医学科学院医学与健康科技创新工程协同创新团队首席科学家、赣江创新人才。2022年入选美国斯坦福大学发布2022年度全球前2%顶尖科学家榜单。 目前在APSB等多种学术期刊担任编委和审稿人。主持和承担国家自然科学基金，北京市自然科学基金和科技部项目。 一共发表科研论文130余篇，其中在Journal of Clinical Investigation (JCI)， Signal Transduction and Targeted Therapy， PNAS， Cancer research， Oncogene， Journal of Investigative Dermatology ，Cancer letter，Acta Pharmaceutica Sinica B等世界著名期刊发表SCI论文100余篇文章。

主要从事肿瘤的机制研究和抗肿瘤相关药物靶点的确认、药物筛选模型的建立及药物筛选、以及活性化合物的深入评价工作、利用人工智能、生物信息学和网络药理学研发新药。

1. Tang Q, Li W, Zheng X, Ren L, Liu J, Li S, Wang J*, Du G*. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduct Target Ther. 2021 6(1):83-94.（IF: 38.104）
2. Yumin Wang, Yan Wang, Harsh Pate, Jichao Chen, Jinhua Wang*, Zhe-Sheng Chen*, Hongquan Wang*. Epigenetic modification of m6A regulator proteins in cancer. Mol Cancer. 2023 Jun 30;22(1):10.（IF:41.4）.
3. Yumin Wang, Jing Hu, Shuang Wu, Joshua S Fleishman , Yulin Li, Yinshi Xu , Wailong Zou, Jinhua Wang* , Yukuan Feng *, Jichao Chen*, Hongquan Wang *. Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases. Signal Transduct Target Ther. 2023 Dec 10;8(1):449.（IF:39.3）.
4. Jinhua Wang#, Ying Qu#, Partha S. Ray et al. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. Journal of Clinical Investigation. 2011;121(1):212-225. (The article was elected as highlighted article) (IF: 15.366)
5. Wan Li, Hongqing Cai, Liwen Ren, Yihui Yang, Hong Yang, Jinyi Liu, Sha Li, Yizhi Zhang, Xiangjin Zheng, Wei Tan, Guanhua Du*, Jinhua Wang* Sphingosine kinase 1 promotes growth of glioblastoma by increasing inflammation mediated by NF-κB /IL-6/STAT3 and JNK/ PTX3 pathways. Acta Pharm Sin B. 2022;12(12):4390-4406（IF: 14.903）
7. Xiangjin Zheng, Wan Li, Huanli Xu, Jinyi Liua, Liwen Ren Yihui Yang, Sha Li, Jinhua Wang*, Tengfei Ji*, Guanhua Du*. Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria dependent apoptosis and autophagy by PI3K/ AKT/mTOR and AMPK/mTOR pathway. Acta Pharmaceutica Sinica B ,2021, 11（11）:3465-3480. (IF:14.903)
8. Jinyi Liu, Jinhua Wang*, et al. The biology, function, and applications of exosomes in cancer. Acta Pharmaceutica Sinica B ,2021，11(19):2783-2797. (IF:14.903)
9. Hong Yang, Xiangjin Zhen, Yihui Yang, Yizhi Zhang, Sen Zhang, Yue Hao, Guanhua Du, Hongquan Wang, Bailin Zhang, Wan Li, Jinhua Wang*. ERCC6L facilitates the onset of mammary neoplasia and promotes the high malignance of breast cancer by accelerating the cell cycle..J Exp Clin Cancer Res. 2023 Sep 4;42(1):227. (IF: 11.3)
10. Wan Li, Liwen Ren, Xiangjin Zheng, Jinyi Liu, Jinhua Wang*, Tengfei Ji*, Guanhua Du*. 3-O-Acetyl-11-keto-β-boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma. Acta Pharmaceutica Sinica B, 2020, 10(2): 301-12. (IF:11.614)
11. Liu J, Zheng X, Li W, Ren L, Li S, Yang Y, Yang H, Ge B, Du G, Shi J, Wang J*. Anti-tumor effects of Skp2 inhibitor AAA-237 on NSCLC by arresting cell cycle at G0/G1 phase and inducing senescence. Pharmacol Res. 2022 Jul;181:106259.（IF: 10.334）
12.Ren L, Yi J, Yang Y, Li W, Zheng X, Liu J, Li S, Yang H, Zhang Y, Ge B, Zhang S, Fu W, Dong D, Du G*, Wang X*, Wang J*. Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis. Pharmacol Res. 2022 Jul 30;183:106376. （IF: 10.334）
13. Xiangjin Zheng, Wan Li, Liwen Ren, Jinyi Liu, Jinhua Wang*. The Sphingosine Kinase-1 / Sphingosine-1-Phosphate Axis in Cancer: Potential Target for Anticancer Therapy. Pharmacology & Therapeutics. 2019 Mar;195:85-99. (IF: 10.376).
14. Jinhua Wang, Wan Li, Ying Zhao et al. Members of FOX family could be drug targets of cancers. Pharmacol Ther. 2018 Jan;181:183-196. (IF: 11)
15.Zhihua Liu, Yahui Zhao, Yang Li, Rui Zhu, Riyue Feng, Heyang Cui, Xiao Yu, Furong Huang, Ruixiang Zhang, Xiankai Chen, Lei Li, Yinghui Chen, Yuhao Liu, Jinhua Wang, and Guanhua Du. RPS15 interated with IGFBP1 to promote esophageal squamous cell carcinoma development via recognizing m6A modification. Signal Transduct Target Ther. 2023.Accepted（IF: 38.104）
16. Ren L, Yang Y, Li W, Zheng X, Liu J, Li S, Yang H, Zhang Y, Ge B, Zhang S, Fu W, Dong D, Du G, Wang J*. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. J Transl Med. 2022 Oct 2;20(1):444 (IF:8.440)
17. Yi-Hui Yang , Wan Li, Li-Wen Ren , Hong Yang, Yi-Zhi Zhang , Sen Zhang , Guan-Hua Du , Jian-You Shi*, Jin-Hua Wang*. S670, an amide derivative of 3-O-acetyl-11-keto-β-boswellic acid, induces ferroptosis in human glioblastoma cells by generating ROS and inhibiting STX17-mediated fusion of autophagosome and lysosome. Acta Pharmacol Sin. 2023 Sep 25. doi: 10.1038/s41401-023-01157-9. (IF: 8.2)
18. Yang Y, Ren L, Li W, Zhang Y, Zhang S, Ge B, Yang H, Du G, Tang B, Wang H, Wang J*. GABAergic signaling as a potential therapeutic target in cancers. Biomed Pharmacother. 2023 May;161:114410. (IF= 7.419)
19. Ren LW, Li W, Zheng XJ, Liu JY, Yang YH, Li S, Zhang S, Fu WQ, Xiao B, Wang JH*, Du GH*. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. Acta Pharmacol Sin. 2022 Jan;43(1):194-208. (IF: 7.189)
20．Li S, Yang H, Li W, Liu JY, Ren LW, Yang YH, Ge BB, Zhang YZ, Fu WQ, Zheng XJ, Du GH*, Wang JH*. ADH1C inhibits progression of colorectal cancer through the ADH1C/PHGDH /PSAT1/serine metabolic pathway. Acta Pharmacol Sin. 2022 Mar 30. (IF: 7.189)
21．Zheng XJ, Chen WL, Yi J, Li W, Liu JY, Fu WQ, Ren LW, Li S, Ge BB, Yang YH, Zhang YZ, Yang H, Du GH, Wang Y, Wang JH*. Apolipoprotein C1 promotes glioblastoma tumorigenesis by reducing KEAP1/NRF2 and CBS-regulated ferroptosis. Acta Pharmacol Sin. 2022 Nov;43(11):2977-2992. (IF: 7.189)
22.Liu JY, Fu WQ, Zheng XJ, Li W, Ren LW, Wang JH*, Yang C*, Du GH*. Avasimibe exerts anticancer effects on human glioblastoma cells via inducing cell apoptosis and cell cycle arrest. Acta Pharmacol Sin. 2021 Jan;42(1):97-107. (IF: 7.189)
23.Jinhua Wang, Sharon Hunag, Ling Takeshima et al. Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas. Journal of Investigative Dermatology. 2015; 135:532-541. (IF: 7.216)
24.Jinhua Wang, Kelly K. Chong, Yoshitaka Nakamura et al. B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma. Journal of Investigative Dermatology. 2013; 133(8):2050-8. (IF: 6.19)
25. Jinhua Wang, Ying Qu, Xiaojiang Cui et al. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kB signaling. Oncogene, 2012 Nov 8;31(45):4798-802. (IF: 7.18)
26. Jinhua Wang*, Partha S. Ray*, Ying Qu* et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Research. 2010; 70(10):1-7. (The pictures in the article were chosen as the cover of magazine) (IF: 8.576)
27. Jinhua Wang, I Kuiatse, AJ Casa, AV Lee, X Cui. JNK, essential for anticancer therapy-induced apoptosis promotes cancer breast progession. Cancer Research. 2009; 69( suppl.):(2).January 15,2009 (IF: 8.576)
28. Yang, H., Li, W., Ren, L., Yang, Y., Zhang, Y. Wang J*.et al. (2023). Progress on diagnostic and prognostic markers of pancreatic cancer. Oncology Research, 31(2), 83–99.
29.Ren L, Yang Y, Li W, Yang H, Zhang Y, Ge B, Zhang S, Du G and Wang J* (2023) Recent advances in epigenetic anticancer therapeutics and future perspectives. Front. Genet. 13:1085391. doi: 10.3389/fgene.2022.1085391(IF: 4.772)
30.Ge B, Wang X, Li W, Li S, Du Y, Ji T, Du G, Fang C, Wang J*. A sensitive LC-MS method for the determination of Sinomenine derivative SWX and its application to pharmacokinetic research in rats. J Chromatogr B. 2022 Dec 15;1213:123474.(IF: 3.318)
31.Li S, Liu J, Zheng X, Ren L, Yang Y, Li W, Fu W, Wang J*, Du G*. Tumorigenic bacteria in colorectal cancer: mechanisms and treatments. Cancer Biol Med. 2021 Sep 30;19(2):147–62. (IF=4.248)
32.Zheng X, Tang Q, Ren L, Liu J, Li W, Fu W, Wang J*, Du G*. A narrative review of research progress on drug therapies for glioblastoma multiforme. Ann Transl Med. 2021 Jun;9(11):943. (IF=3.932)
33. Jie Yi, Liwen Ren, Dandan Li, Jie Wu, Wan Li, Guanhua Du, Jinhua Wang*. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers [J]. Biomedicine & Pharmacotherapy, 2020, 124(109827). (IF: 4.545)
34. Jie Yi, Liwen Ren, Jie Wu, Wan Li, Xiangjin Zheng, Guanhua Du*, Jinhua Wang*. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer. Ann Transl Med. 2019 Aug;7(16):380. (IF: 3.689)
35. Qin Tang, Liwen Ren, Jinyi Liu, Wan Li, Xiangjin Zheng, Jinhua Wang*, Guanhua Du*. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4‐ATF3-CHOP axis. Cell Prolif. 2019 Oct 23:e12706. (IF: 5.039)
36. Liwen Ren, Xiangjin Zheng, Jinyi Liu, Wan Li, Weiqi Fu, Qin Tang, Jinhua Wang*, Guanhua Du*. Network pharmacology study of traditional Chinese medicines for stroke treatment and effective constituents screening. J Ethnopharmacol. 2019 Oct 5;242:112044.(IF: 3.414)
37. Jinyi Liu，Xiangjin Zheng，Xiaocong Pang, Cui Yang, Jinhua Wang*. GD3s，a novel drug target of cancer. Acta Pharmaceutica Sinica B. 2018 Sep;8(5):713-720.（IF: 5.808）
38. Wan Li, Jie Yi, Xiangjin Zheng, Shiwei Liu, Weiqi Fu, Liwen Ren, Li Li, Dave S. B. Hoon, Jinhua Wang*, Guanhua Du. miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clinical Epigenetics. 2018 May 16;10:64.. (IF: 5.496 )
39. Jinhua Wang, Hirose H, Du G et al. P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway. Cancer Lett. 2017 Oct 28;407:66-75. (IF: 6.491)
40. Jie Yu, Jinhua Wang* et al. Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. Oncotarget. 2017 Mar 28; 8(13):20751-20765. (IF: 5.168)

1. 《丹参大全》. ISBN:978-7-117-09935-6/R.9936、编者、人民卫生出版社、2008出版
2. 《人类疾病动物模型》. ISBN: 978-7-81116-231-8. 编者 2007出版
3. 《天然小分子药物-源自于植物的小分子药物》副主编、人民卫生出版社、 2018出版
4. 《中药材“毒”之古今研究概评》 编委、 中国医药科技出版社、 2018出版
5. 《Nature small molecule drugs from plants》 编委 Springer Nature Singapore Pte Ltd. and People’s Medical Publishing House、2019 出版
6. 《中国医学科技发展报告》、编者、科学出版社2019出版
7. 《实验药理学（第2版）》，副主编，高等教育出版社，2020年出版。2021出版
8. 《漫话糖尿病》、编委、科学出版社、2017出版
9．《糖尿病生活百科》编委 、科学出版社、2018出版

国际专利：
1. Patent 1: METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PRIMARY AND METASTATIC BASAL-LIKE BREAST CANCER AND OTHER CANCER TYPES （Patent No. US 9074253 B2 授权日： 2015.7.7）.
2. Patent 2: DIAGNOSIS OF PRIMARY AND METASTATIC BASAL-LIKE BREAST CANCER AND OTHER CANCER TYPES （Patent No. EP 2486149 B1 授权日： 2015.6.17）.
国内专利：
3. 专利1：醉茄素A在制备预防或治疗胶质母细胞瘤药物中的应用。王金华等。申请号：201810266304.0
4. 专利2：乳香酸及其衍生物的制备与其抗神经胶质瘤的用途。王金华等。申请号：201810581480.3
5. 专利 3：阿伐麦布在制备预防或治疗胶质母细胞瘤药物中的应用。 王金华等。申请号：201811248470.4
6. 专利 4：载脂蛋白C 1在作为胃癌诊断及预后评价生物标记物中的应用。王金华等。申请号：201910163695.8
7. 专利 5：青藤碱类化合物在制备预防或治疗神经胶质瘤药物中的应用。王金华等。申请号：201910671599.4
8. 专利 6：三个唑类化合物在制备抗神经胶质瘤药物中的应用。王金华等。申请号：202010189295.7
9. 专利 7：黄芩素在制备预防和/或治疗新冠病毒感染疾病的药物中的应用。杜冠华，吕扬….王金华等。申请号：202010133944.1